Myriad Asset Management Ltd. Increases Stake in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)
Myriad Asset Management Ltd. Increases Stake in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)
Myriad Asset Management Ltd. raised its position in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN – Get Rating) by 53.7% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 22,127 shares of the company's stock after purchasing an additional 7,727 shares during the period. Biohaven Pharmaceutical accounts for approximately 0.4% of Myriad Asset Management Ltd.'s portfolio, making the stock its 26th biggest holding. Myriad Asset Management Ltd.'s holdings in Biohaven Pharmaceutical were worth $2,624,000 at the end of the most recent quarter.
据Myriad Asset Management Ltd.最近提交给美国证券交易委员会的文件显示,该公司今年第一季度将其在Bioaven Pharmtics Holding Company Ltd.的持仓上调了53.7%。该机构投资者持有22,127股该公司股票,在此期间又购买了7,727股。生物港药业在Myriad Asset Management Ltd.的投资组合中约占0.4%,使该股成为其第26大持股。截至最近一个季度末,Myriad Asset Management Ltd.持有的生物港药业股份价值2,62.4万美元。
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Capital World Investors lifted its holdings in Biohaven Pharmaceutical by 1.9% in the 4th quarter. Capital World Investors now owns 6,178,009 shares of the company's stock valued at $851,391,000 after purchasing an additional 115,628 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Biohaven Pharmaceutical by 0.5% during the 1st quarter. BlackRock Inc. now owns 4,656,866 shares of the company's stock worth $552,163,000 after acquiring an additional 21,586 shares during the period. Stifel Financial Corp raised its holdings in shares of Biohaven Pharmaceutical by 1.9% during the 4th quarter. Stifel Financial Corp now owns 3,049,995 shares of the company's stock worth $420,319,000 after acquiring an additional 55,650 shares during the period. Marshall Wace LLP raised its holdings in shares of Biohaven Pharmaceutical by 3.0% during the 4th quarter. Marshall Wace LLP now owns 2,798,457 shares of the company's stock worth $385,657,000 after acquiring an additional 80,272 shares during the period. Finally, State Street Corp raised its holdings in shares of Biohaven Pharmaceutical by 11.0% during the 4th quarter. State Street Corp now owns 1,647,694 shares of the company's stock worth $227,069,000 after acquiring an additional 162,764 shares during the period. Hedge funds and other institutional investors own 78.19% of the company's stock.
其他一些对冲基金和其他机构投资者最近也增持或减持了该公司的股份。资本世界投资者在第四季度增持了生物港制药1.9%的股份。Capital World Investors现在持有该公司6,178,009股股票,价值851,391,000美元,上个季度又购买了115,628股。贝莱德股份有限公司在第一季度增持了生物港药业的股份,增幅为0.5%。贝莱德股份有限公司在此期间增持了21,586股,目前持有该公司4,656,866股股票,价值552,163,000美元。Stifel Financial Corp在第四季度将其在Bioaven Pharmtics的股票持有量增加了1.9%。Stifel Financial Corp目前持有该公司3,049,995股股票,价值420,319,000美元,在此期间额外购买了55,650股票。马歇尔·华斯有限责任公司在第四季度增持了生物港药业3.0%的股票。马歇尔·华斯有限责任公司在此期间额外收购了80,272股,现在拥有2,798,457股公司股票,价值385,657,000美元。最后,道富集团在第四季度增持了生物港药业11.0%的股票。道富银行目前持有1,647,694股该公司股票,价值227,069,000美元,在此期间又收购了162,764股。对冲基金和其他机构投资者持有该公司78.19%的股份。
Insider Buying and Selling at Biohaven Pharmaceutical
生物港药业的内幕买卖
In related news, Director Gregory Bailey bought 38,000 shares of the company's stock in a transaction dated Friday, August 19th. The shares were acquired at an average price of $148.04 per share, with a total value of $5,625,520.00. Following the completion of the acquisition, the director now owns 2,583,658 shares in the company, valued at approximately $382,484,730.32. The transaction was disclosed in a document filed with the SEC, which is available through this link. 12.40% of the stock is owned by company insiders.
在相关新闻中,董事格雷戈里·贝利在一笔日期为8月19日(星期五)的交易中购买了38,000股该公司股票。这些股票是以每股148.04美元的平均价格收购的,总价值为5,625,520.00美元。收购完成后,董事现在拥有该公司2,583,658股,价值约382,484,730.32美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,可以通过这个链接获得。12.40%的股份由公司内部人士持有。
Analyst Ratings Changes
分析师评级发生变化
Biohaven Pharmaceutical Price Performance
生物港药品价格表现
Shares of Biohaven Pharmaceutical stock opened at $150.71 on Friday. The business has a 50-day simple moving average of $147.28 and a 200-day simple moving average of $133.13. Biohaven Pharmaceutical Holding Company Ltd. has a one year low of $79.01 and a one year high of $151.51.
生物港药业的股票周五开盘报150.71美元。该业务的50日简单移动均线切入位在147.28美元,200日简单移动均线切入位在133.13美元。生物港药业控股有限公司的股价一年来最低为79.01美元,一年最高为151.51美元。
Biohaven Pharmaceutical (NYSE:BHVN – Get Rating) last issued its quarterly earnings data on Friday, August 5th. The company reported ($6.21) earnings per share for the quarter, missing analysts' consensus estimates of ($2.79) by ($3.42). The business had revenue of $215.08 million during the quarter, compared to the consensus estimate of $209.33 million. As a group, equities research analysts forecast that Biohaven Pharmaceutical Holding Company Ltd. will post -13.29 earnings per share for the current year.
生物港制药公司(纽约证券交易所代码:BHVN-GET评级)最近一次发布季度收益数据是在8月5日星期五。该公司公布本季度每股收益为6.21美元,低于分析师普遍预期的2.79美元和3.42美元。该业务本季度的收入为2.1508亿美元,而普遍预期为2.0933亿美元。作为一个整体,股票研究分析师预测,Bioaven Pharmtics Holding Company Ltd.今年的每股收益将达到13.29美元。
About Biohaven Pharmaceutical
关于生物港制药公司
(Get Rating)
(获取评级)
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
生物制药公司Bioaven Pharmtics Holding Company Ltd.是一家生物制药公司,在美国开发针对神经和神经精神疾病以及罕见疾病的候选产品。它提供用于偏头痛急性治疗的NURTEC ODT(Riegepant),以及用于偏头痛预防治疗的开发Rimegepant;处于偏头痛急性和预防治疗以及呼吸道并发症和非偏头痛研究的第三阶段临床试验的Zavegepant;以及用于非偏头痛适应症的BHV-3100。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Biohaven Pharmaceutical (BHVN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免费获取StockNews.com关于生物港制药公司(BHVN)的研究报告
- MarketBeat:回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏,这些股票可能表现优异
- DocuSign是否即将发生重大逆转?
- 石油和天然气股票:投资可再生能源的安全途径
Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN – Get Rating).
想看看还有哪些对冲基金持有BHVN吗?访问HoldingsChannel.com,获取Bioaven制药控股有限公司(纽约证券交易所代码:BHVN-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
获得《生物港药学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bioaven制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。